NCT03598309View on ClinicalTrials.gov

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

March 4, 2025

Study Completion Date

May 31, 2026

Conditions
Lung DiseasesLung Cancer, Protection Against
Interventions
DRUG

Curcumin C3 complex®

Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

DRUG

Lovaza®

Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

OTHER

Placebo

Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

James and Esther King Biomedical Research Program

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER